T790M-EGFR mutation frequency in advanced NSCLC patients on progression from a previous TKI therapy: results from a Portuguese study
Saved in:
| Main Authors: | Encarnação Teixeira, António Araújo, Venceslau Hespanhol, Bárbara Parente, Fernando Barata |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis
2021-09-01
|
| Series: | Pulmonology |
| Online Access: | https://www.tandfonline.com/doi/10.1016/j.pulmoe.2021.01.007 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lymphocyte subset-based non-invasive biomarker predicts immunochemotherapy efficacy in EGFR-TKI-pretreated EGFR-mutated NSCLC
by: Lianxi Song, et al.
Published: (2025-09-01) -
Intracellular cholesterol: new functions and therapeutic approaches in NSCLC EGFR-TKI resistance
by: Linjuan Wang, et al.
Published: (2025-07-01) -
Real-world prognostic factors for first-line EGFR-TKI efficacy in advanced NSCLC patients harboring EGFR 21 L858R mutation
by: Yan’e Liu, et al.
Published: (2025-06-01) -
Non-invasive identification of TKI-resistant NSCLC: a multi-model AI approach for predicting EGFR/TP53 co-mutations
by: Jiayi Li, et al.
Published: (2025-07-01) -
Real-world analysis of survival outcomes in advanced EGFR-mutant NSCLC patients treated with platinum-pemetrexed after EGFR-TKI treatment failure
by: Zong-Han Yao, et al.
Published: (2025-08-01)